Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072123 | 0.85 | TRPV1 (0.56) | TRPV1ABL1HCAR2DHFR | |
| SCHEMBL5802992 | 0.83 | TRPV1 (0.75) | TRPV1VCPJAK2HCAR2CYP46A1 | |
| SCHEMBL5801390 | 0.81 | TRPV1 (0.52) | TRPV1VCPHCAR2ME3MALT1 | |
| SCHEMBL5801385 | 0.81 | TRPV1 (0.50) | TRPV1VCPJAK2ADORA1ADORA3 | |
| SCHEMBL6072397 | 0.76 | TRPV1 (0.68) | TRPV1JAK2HCAR2CYP46A1ME3 | |
| SCHEMBL5802758 | 0.75 | HSD17B10 (0.58) | VCPMKNK1 | |
| SCHEMBL5802659 | 0.75 | TRPV1 (0.76) | TRPV1HCAR2ME3MALT1 | |
| SCHEMBL5799181 | 0.74 | NOTUM (0.59) | — | |
| SCHEMBL18376734 | 0.74 | JAK2 (0.56) | JAK2ABL1JAK1 | |
| SCHEMBL6071865 | 0.73 | MALT1 (0.50) | TRPV1VCPCYP46A1ME3MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | TRPV1 2/4885VCP 869/4885JAK2 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.